Drug
Ft825
Ft825: highest development phase Phase 1, developed by Fate Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Fate Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| FT825 NCT06241456 | Phase 1 | Advanced Solid Tumor |
Latest
No recent events.
Follow Ft825 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.